$181 Million is the total value of Sio Capital Management, LLC's 49 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRIS | Exit | CURIS INC | $0 | – | -834,551 | -100.0% | -0.33% | – |
| HRTX | Exit | HERON THERAPEUTICS INCput | $0 | – | -29,500 | -100.0% | -0.49% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -72,826 | -100.0% | -0.78% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -190,300 | -100.0% | -0.91% | – |
| JNJ | Exit | JOHNSON & JOHNSONput | $0 | – | -20,000 | -100.0% | -1.54% | – |
| MYL | Exit | MYLAN NV | $0 | – | -69,000 | -100.0% | -1.71% | – |
| IMGN | Exit | IMMUNOGEN INCput | $0 | – | -274,800 | -100.0% | -1.74% | – |
| OMCL | Exit | OMNICELL INC | $0 | – | -70,226 | -100.0% | -1.83% | – |
| CPSI | Exit | COMPUTER PROGRAMS AND SYSTEMS INC | $0 | – | -113,860 | -100.0% | -2.00% | – |
| MRK | Exit | MERCK & CO INC | $0 | – | -114,856 | -100.0% | -3.76% | – |
| LLY | Exit | ELI LILLY AND CO | $0 | – | -82,363 | -100.0% | -3.83% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -31,900 | -100.0% | -5.25% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.